undamentalytics Newsletter
Sign in

Pacific Biosciences Of California, Inc. cash flow statement

In fiscal 2025, Pacific Biosciences Of California, Inc.'s operations generated −$111m of cash; it spent $2.7m on capital projects, leaving free cash flow of −$114m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2009Dec 20092010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations−75−122−103−77−30−51−48−68−68−66−7820−111−263−259−206−111−118
Depreciation and amortisation4567644487767911141310
Stock-based pay41012101010142020231618737972714234
Capital spending55921238102316179635
Free cash flow−80−127−112−79−31−53−51−76−78−68−8118−117−280−268−212−114−123
Free cash flow after stock pay−84−137−125−88−41−63−65−96−98−91−981−190−359−340−283−156−158
Share buybacks0—————————————————
Shares issued021383347891094632018900—

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: GRAL vs PACBPACB vs QTRXCYRX vs PACB

More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies

Figures from Pacific Biosciences Of California, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Pacific Biosciences Of California, Inc.